Answers are grounded in this paper and cite their sources.
Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive cancer with no standardized perioperative treatment. This study aimed to explore the efficacy and safety of perioperative immunochemotherapy with envafolimab for resectable PLCNEC. We report a 67-year-old male patient with stage IIIA PLCNEC (cT4N0M0) who received four cycles of neoadjuvant immunochemotherapy (envafolimab + carboplatin + etoposide), followed by radical surgery and adjuvant therapy. After neoadjuvant treatment, the tumor shrank by 48.1% and achieved partial response. The patient underwent successful R0 resection and achieved major pathological response. As of May 2025, the patient remained disease-free for 29 months postoperatively, with no grade greater than or equal to 3 adverse events. Notably, clinical benefit was achieved despite negative programmed death-ligand 1 (PD-L1) expression. Perioperative immunochemotherapy with envafolimab is a promising therapeutic option for patients with resectable PLCNEC, even in those with negative PD-L1 expression.
No takes yet. Share an insight, caveat, or question.
Long et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: